Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium

定义输卵管上皮的癌前表型

基本信息

  • 批准号:
    8068733
  • 负责人:
  • 金额:
    $ 31.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-05-08 至 2014-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The lack of an identifiable precursor lesion for ovarian carcinoma hinders attempts to design rational surveillance and chemoprevention for this deadly disease. Indeed, it is uncertain which are the specific cells in the female genital tract that transform into ovarian and primary peritoneal malignancies. A better understanding of the early steps in ovarian tumorigenesis would facilitate the development of new screening and prevention strategies. Inherited mutations in the BRCA1 gene result in an approximate 40% lifetime risk of ovarian, tubal or peritoneal carcinoma. Current clinical recommendations for women with BRCA1 mutations include risk-reducing salpingo-oophorectomy (RRSO) by age 40 after completion of child-bearing. Our group and others have identified a high rate of high-grade serous neoplasia in the fallopian tubes of BRCA1 mutation carriers undergoing RRSO. The frequency of occult tubal neoplasia exceeds that of ovarian neoplasia when using a detailed surgical and pathological protocol. We hypothesize that most ovarian and peritoneal carcinomas arising in BRCA1 mutation carriers are seeded from neoplastic cells arising in the fallopian tubes. This phenomenon could have important implications for the development of sporadic as well as hereditary ovarian carcinoma. The overall goal of the current proposal is to define a premalignant tubal phenotype in women with inherited BRCA1 mutations. The specific aims of this proposal are: 1. Characterize tubal epithelium in unaffected women with BRCA1 mutations and in women with BRCA1- associated or sporadic ovarian and peritoneal carcinomas. 2. Identify and characterize a gene expression signature associated with premalignant alterations in pathologically normal tubal epithelium from women with BRCA1 mutations. 3. Evaluate priority genes from Specific Aim 2 in inherited and sporadic ovarian and peritoneal carcinomas. PUBLIC HEALTH RELEVANCE: An improved understanding of the early steps in ovarian carcinoma development is needed to facilitate rational and novel strategies for screening and prevention. Identification of a pre-cursor lesion for ovarian and peritoneal carcinoma and proof of its potential for malignant progression would facilitate chemoprevention trials in high-risk women and provide new targets for early detection.
描述(由申请人提供):缺乏可识别的卵巢癌前病变阻碍了对这种致命疾病进行合理监测和化学预防的尝试。事实上,目前还不确定哪些是女性生殖道中转化为卵巢和原发性腹膜恶性肿瘤的特定细胞。更好地了解卵巢肿瘤发生的早期步骤将有助于制定新的筛查和预防策略。BRCA1基因的遗传突变导致大约40%的卵巢癌、输卵管癌或腹膜癌的终生风险。目前对BRCA1突变女性的临床建议包括在40岁完成生育后进行输卵管卵巢切除术(RRSO)以降低风险。我们的研究小组和其他研究小组已经发现,在接受RRSO的BRCA 1突变携带者中,输卵管高度恶性浆液性肿瘤的发生率很高。当使用详细的手术和病理方案时,隐匿性输卵管肿瘤的发生率超过卵巢肿瘤。我们假设大多数BRCA1突变携带者的卵巢癌和腹膜癌是由输卵管中的肿瘤细胞引起的。这种现象可能对散发性和遗传性卵巢癌的发展有重要意义。目前建议的总体目标是确定遗传性BRCA1突变妇女的癌前输卵管表型。该提案的具体目标是:1.描述未受影响的BRCA1突变女性和BRCA1相关或散发性卵巢癌和腹膜癌女性的输卵管上皮特征。2.鉴定和表征BRCA1突变妇女病理正常输卵管上皮癌前病变相关的基因表达特征3.评估遗传性和散发性卵巢癌和腹膜癌中特异性目标2的优先基因。公共卫生关系:需要对卵巢癌发展的早期步骤有更好的理解,以促进合理和新的筛查和预防策略。确定卵巢癌和腹膜癌的前体病变并证明其恶性进展的可能性,将有助于在高危妇女中进行化学预防试验,并为早期检测提供新的靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ELIZABETH MARY SWISHER其他文献

ELIZABETH MARY SWISHER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ELIZABETH MARY SWISHER', 18)}}的其他基金

Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer
卵巢癌患者的克隆性造血和治疗引起的骨髓肿瘤
  • 批准号:
    10661251
  • 财政年份:
    2023
  • 资助金额:
    $ 31.4万
  • 项目类别:
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy
甲基化和突变检测以个性化 PARP 抑制剂治疗
  • 批准号:
    10028143
  • 财政年份:
    2020
  • 资助金额:
    $ 31.4万
  • 项目类别:
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy
甲基化和突变检测以个性化 PARP 抑制剂治疗
  • 批准号:
    10405502
  • 财政年份:
    2020
  • 资助金额:
    $ 31.4万
  • 项目类别:
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy
甲基化和突变检测以个性化 PARP 抑制剂治疗
  • 批准号:
    10200719
  • 财政年份:
    2020
  • 资助金额:
    $ 31.4万
  • 项目类别:
Combined Methylation and Mutation to Predict Response to PARP Inhibitors
结合甲基化和突变来预测对 PARP 抑制剂的反应
  • 批准号:
    9893364
  • 财政年份:
    2020
  • 资助金额:
    $ 31.4万
  • 项目类别:
Combined Methylation and Mutation to Predict Response to PARP Inhibitors
结合甲基化和突变来预测对 PARP 抑制剂的反应
  • 批准号:
    10378133
  • 财政年份:
    2020
  • 资助金额:
    $ 31.4万
  • 项目类别:
Combined Methylation and Mutation to Predict Response to PARP Inhibitors
结合甲基化和突变来预测对 PARP 抑制剂的反应
  • 批准号:
    10670755
  • 财政年份:
    2020
  • 资助金额:
    $ 31.4万
  • 项目类别:
Implementing the moon: Getting genomic testing to the public
实施月球:向公众进行基因组测试
  • 批准号:
    10228866
  • 财政年份:
    2019
  • 资助金额:
    $ 31.4万
  • 项目类别:
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
定义输卵管上皮的癌前表型
  • 批准号:
    7648344
  • 财政年份:
    2009
  • 资助金额:
    $ 31.4万
  • 项目类别:
Defining a Pre-Malignant Phenotype in Fallopian Tube Epithelium
定义输卵管上皮的癌前表型
  • 批准号:
    7837669
  • 财政年份:
    2009
  • 资助金额:
    $ 31.4万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 31.4万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 31.4万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 31.4万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 31.4万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 31.4万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 31.4万
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 31.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 31.4万
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 31.4万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 31.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了